Profile
Jon Davies worked as a Director of Investor Relations and Communications at Xenova Group Plc, Director of Communications and Investor Relations at Touchstone Innovations Ltd., and Director of Investor Relations and Communications at Datatec Ltd.
He also worked as the Head of Investor Relations at Horizon Discovery Group Ltd.
from 2019 to 2021.
Dr. Davies received an undergraduate degree from the University of London and a doctorate degree from the University of Sussex.
Former positions of Jon Davies
| Companies | Position | End |
|---|---|---|
| HORIZON DISCOVERY GROUP PLC | Investor Relations Contact | 2021-08-31 |
Xenova Group Plc
 Xenova Group Plc Miscellaneous Commercial ServicesCommercial Services Xenova Group Plc researches and develops pharmaceutical products. The company is focused on the development of novel drugs to treat cancer and addiction with a secondary focus in immunotherapy. It has pipeline of drug candidates in clinical development including a novel program for the treatment of high-grade glioma and TransMID. The company was founded in 1987 and is headquartered in Slough, UK | Investor Relations Contact | - |
| DATATEC LIMITED | Investor Relations Contact | - |
| TOUCHSTONE INNOVATIONS PLC | Investor Relations Contact | - |
Training of Jon Davies
| University of Sussex | Doctorate Degree |
| University of London | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| DATATEC LIMITED | Technology Services |
| Private companies | 3 |
|---|---|
Touchstone Innovations Ltd.
 Touchstone Innovations Ltd. Investment ManagersFinance Touchstone Innovations Ltd. engages in the provision of technology and commercialization services. The company was founded by Susan Jane Searle in 1986 and is headquartered in London, the United Kingdom. | Finance |
Xenova Group Plc
Xenova Group Plc Miscellaneous Commercial ServicesCommercial Services Xenova Group Plc researches and develops pharmaceutical products. The company is focused on the development of novel drugs to treat cancer and addiction with a secondary focus in immunotherapy. It has pipeline of drug candidates in clinical development including a novel program for the treatment of high-grade glioma and TransMID. The company was founded in 1987 and is headquartered in Slough, UK | Commercial Services |
Horizon Discovery Group Ltd.
 Horizon Discovery Group Ltd. Medical SpecialtiesHealth Technology Horizon Discovery Group Ltd. is a cell engineering company, which engages in the design and engineering of genetically-modified cells. The firm operates through the following business segments: Products, Services, and Leveraged Research & Development. The Products segment sells cell lines and other products. The Services segment offers cell line manufacturing services. The Leveraged Research & Development segment business unit is operated on a portfolio basis. It serves pharmaceutical, biotechnology, and diagnostic companies. The company was founded by Christopher John Torrance, Adam John Collier, and Alberto Bardelli in July 2005 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Jon Davies
